TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (the “Company” or “VitalHub”) (TSX: VHI) (OTCQX: VHIBF) announced today it has filed its Consolidated Financial Statements and Management's Discussion and Analysis report for the year ended December 31, 2024 with the Canadian securities authorities. These documents may be viewed under the Company’s profile at www.sedarplus.com.
“We are pleased to report strong full year results, highlighted by annual 15% organic ARR⁽¹⁻²⁾ growth and 26% adjusted EBITDA⁽²⁾ margins,” said Dan Matlow, CEO of VitalHub. “We are seeing momentum build with our growing platform functionality and reputational awareness. Our record-breaking sequential net new organic ARR⁽¹⁻²⁾ in the fourth quarter of $2.6 million was well-balanced across our leading EHR suite in Canada and patient flow solutions in the UK. We see opportunities for sustained growth rates in our core geographies as we cross-sell complementary solutions and add new clients.”
“We closed four acquisitions in 2024, adding $17.9 million of acquisition ARR⁽¹⁻²⁾ and adding new solutions and team members that we are proud to have at VitalHub. Integration efforts from a product, infrastructure, and go-to-market perspective are well underway, including the fourth quarter 2024 acquisitions of Strata and MedCurrent. We see areas for potential enhanced revenue growth and operational efficiency, with our goal of steadily expanding our cash flow margin over the next twelve to eighteen months post-acquisition, as we have successfully accomplished historically.”
“Our current pro forma cash balance is approximately $90 million, with strong positive cash generation and access to debt if needed. We are prepared to deploy capital on M&A, and we currently expect the pace of activity from 2024 to continue through 2025. We are proud of all growth and achievements to date, and are excited for the year ahead.”
VitalHub’s quarterly investor conference call will take place on Friday, March 28, 2025, at 9:00AM EST.
To register for the call, please visit: https://us06web.zoom.us/webinar/register/WN_rJOjJmU7TXen7-jbFcjXbA#/registration
Fourth Quarter 2024 Highlights
Annual 2024 Highlights
(1) The Company defines annual recurring revenue (“ARR”) as the recurring revenue expected based on yearly subscriptions of the renewable software license fees and maintenance services.
(2) Non-IFRS measure. Disclaimers and reconciliations can be found in SEDAR filings.
Selected Financial Information
Three months ended | Year ended | |||||||||||||
December 31, 2024 | % Revenue | December 31, 2023 | % Revenue | Change | December 31, 2024 | % Revenue | December 31, 2023 | % Revenue | Change | |||||
$ | $ | % | $ | $ | % | |||||||||
Revenue | 20,590,779 | 100% | 13,603,419 | 100% | 51% | 68,594,310 | 100% | 52,508,298 | 100% | 31% | ||||
Cost of sales | 3,841,539 | 19% | 2,364,543 | 17% | (62%) | 13,099,877 | 19% | 9,697,998 | 18% | (35%) | ||||
Gross profit | 16,749,240 | 81% | 11,238,876 | 83% | 49% | 55,494,433 | 81% | 42,810,300 | 82% | 30% | ||||
Operating expenses | ||||||||||||||
General and administrative | 5,442,656 | 26% | 2,911,708 | 21% | (87%) | 15,451,016 | 23% | 11,765,148 | 22% | (31%) | ||||
Sales and marketing | 1,685,221 | 8% | 1,394,948 | 10% | (21%) | 6,766,434 | 10% | 5,883,267 | 11% | (15%) | ||||
Research and development | 4,189,941 | 20% | 3,188,172 | 23% | (31%) | 15,227,119 | 22% | 12,169,285 | 23% | (25%) | ||||
Depreciation of property and equipment | 123,147 | 1% | 76,496 | 1% | (61%) | 375,838 | 1% | 318,866 | 1% | (18%) | ||||
Depreciation of right-of-use assets | 111,156 | 1% | 101,115 | 1% | (10%) | 438,068 | 1% | 399,715 | 1% | (10%) | ||||
Share-based compensation | 684,034 | 3% | 220,494 | 2% | (210%) | 2,344,464 | 3% | 1,058,919 | 2% | (121%) | ||||
Deferred share-based compensation | - | 0% | - | 0% | 0% | - | 0% | 97,560 | 0% | 100% | ||||
Foreign currency loss (gain) | 384,805 | 2% | (241,505 | ) | (2%) | 259% | 209,733 | 0% | (296,824 | ) | (1%) | (171%) | ||
Other expenses (income) | ||||||||||||||
Amortization of intangible assets | 1,730,224 | 8% | 1,067,885 | 8% | (62%) | 5,149,018 | 8% | 4,259,113 | 8% | (21%) | ||||
Business acquisition, restructuring and integration costs | 2,588,292 | 13% | 306,741 | 2% | (744%) | 5,213,044 | 8% | 1,534,835 | 3% | (240%) | ||||
(Gain) loss on change in fair value of contingent consideration | (100,938 | ) | (0%) | 466,045 | 3% | 122% | 331,892 | 0% | 712,370 | 1% | 53% | |||
Interest expense and accretion (net of interest income) | (270,367 | ) | (1%) | (252,294 | ) | (2%) | 7% | (1,950,815 | ) | (3%) | (489,566 | ) | (1%) | 298% |
Interest expense from lease liabilities | 8,210 | 0% | 14,825 | 0% | 45% | 43,005 | 0% | 71,981 | 0% | 40% | ||||
Gain on disposal of property and equipment | (141 | ) | (0%) | - | 0% | 0% | (141 | ) | (0%) | (2,102 | ) | (0%) | 93% | |
Current and deferred income taxes | (614,244 | ) | (3%) | 1,045,457 | 8% | (159%) | 2,896,714 | 4% | 778,248 | 1% | 272% | |||
Net income | 787,244 | 4% | 938,789 | 7% | (16%) | 2,999,044 | 4% | 4,549,485 | 9% | (34%) | ||||
EBITDA (Non-IFRS measure) | 1,875,370 | 9% | 2,992,273 | 22% | (37%) | 9,950,872 | 15% | 9,887,842 | 19% | 1% | ||||
Adjusted EBITDA (Non-IFRS measure) | 5,046,758 | 25% | 3,985,553 | 29% | 27% | 17,840,272 | 26% | 13,291,526 | 25% | 34% | ||||
Annual recurring revenue (Non-IFRS measure) | 71,054,210 | 44,573,739 | 59% | 71,054,210 | 44,573,739 | 59% | ||||||||
Term licences, maintenance and support revenue | 17,673,596 | 86% | 11,302,366 | 83% | 56% | 57,070,350 | 83% | 42,332,253 | 81% | 35% | ||||
As at | ||||||||||||||
December 31, 2024 | December 31, 2023 | |||||||||||||
$ | $ | |||||||||||||
Cash balance | 56,574,904 | 33,480,018 | ||||||||||||
Deferred revenue | 35,636,002 | 21,049,975 |
About VitalHub
VitalHub is a leading software company dedicated to empowering health and human services providers globally. VitalHub's comprehensive product suite includes electronic health records, operational intelligence, and workforce automation solutions that serve over 1,000 clients across the UK, Canada, and other geographies. The Company has a robust two-pronged growth strategy, targeting organic opportunities within its product suite and pursuing an aggressive M&A plan. VitalHub is headquartered in Toronto with over 500 employees globally, across key regions and the VitalHub Innovations Lab in Sri Lanka. For more information about VitalHub (TSX: VHI) (OTCQX: VHIBF), please visit www.vitalhub.com and connect with us on LinkedIn.
Contact Information
Christian Sgro, CPA, CA, CFA
Head of IR and M&A Specialist
(365) 363-6433
This email address is being protected from spambots. You need JavaScript enabled to view it.
Dan Matlow
Chief Executive Officer, Director
(416) 727-9061
This email address is being protected from spambots. You need JavaScript enabled to view it.
Cautionary Statement
Certain statements contained in this news release may constitute "forward-looking information" or "financial outlook" within the meaning of applicable securities laws that involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information or financial outlook. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
Last Trade: | C$10.24 |
Daily Change: | 0.58 6.00 |
Daily Volume: | 496,030 |
Market Cap: | C$538.730M |
January 09, 2025 December 17, 2024 November 13, 2024 October 30, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load